73P Impact of assessment-to-treatment interval on the predictive value of PD-L1 expression in melanoma
A PD-L1 expression ≥ 1% in tumor tissue from patients with metastatic melanoma is associated with improved survival and may serve as a tool for selecting the optimal first-line immune checkpoint inhibitor (ICI) regime. However, the impact of the interval between PD-L1 assessment and ICI initiation on its predictive value remains unclarified.
Authors
- A.A. Luczak
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Henrik Schmidt (ORCID: https://orcid.org/0000-0003-1080-3344)
- Christian Vestergaard (ORCID: https://orcid.org/0000-0001-6485-3158)
- M. Donia
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100816
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis